New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes
DeNobio
DeNobio
Sponsor study identifier
observational
210
1 country
1
Study Start
January 15, 2022
Actual (reported)Primary Completion
January 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 15, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients. The investigators will use this project to better characterize AE and PNS patients to identify new diagnostic and prognostic biomarkers and develop new diagnostic tools.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 15, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 15, 2022
Actual (reported)November 21, 2022
Actual (reported)February 15, 2023
Actual (reported)January 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 15, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Description of new biomarkers
Results of diagnostics tests for each patient, description of marking
Baseline
Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patient without antibodies known with neurological disorder and include in biobank of "centre de reference des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes".
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes
Lyon, 69677, France
Blood samples (0.5ml), CSF cerebrospinal Fluid (0.2ml), buffy coat (0.5ml), cells or tumors (FFPE block) have been collected in SNP collection
First Submitted
November 21, 2022
First Posted
February 15, 2023
Study Start
January 15, 2022
Actual (reported)Primary Completion
January 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Contact the study team to confirm eligibility.
Study Completion
January 15, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 15, 2023
Record last verified: 2023-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: